Skip to main content

Elaine E. Weiner, MD

Academic Title:

Associate Professor

Primary Appointment:


Additional Title:

Assistant Professor/Medical Director MPRC, Outpatient Research Program and First Episode Clinic Department of Psychiatry University of Maryland School of Medicine


Maryland Psychiatric Research Center, Outpatient Research Program

Phone (Primary):

(410) 402-7694



Education and Training

The George Washington University, Washington,  DC B.A. 1983 Pre-Medicine

UHS/The Chicago Medical School, N. Chicago,   IL M.D. 1988 Medicine

University of Maryland, Baltimore, MD Residency 1992 General Psychiatry




As Medical Director in the Outpatient Research Program and the First Episode Clinic of the Maryland Psychiatric Research Center, it is my responsibility to ensure that persons in our care obtain state of the art psychiatric care.  I perform direct care, supervision of social workers and training psychiatrists, and a myriad of administrative tasks. As part of Program’s mission, I support the ongoing production of clinical research and have intermittently functioned as a primary investigator. Smoking cessation has been a research interest and an ongoing clinical goal of mine.

Research/Clinical Keywords

Pharmacologic and Psychosocial Treatment of Schizophrenia Smoking Cessation in Schizophrenia

Highlighted Publications

Weiner E, Ball P, Summerfelt A, Gold J, Buchanan RW.  Effects of sustained-release buproprion and supportive group therapy on cigarette consumption in patients with schizophrenia.  American Journal of Psychiatry 158(4):635-637, 2001.

Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW.  Adjunctive Risperidone for partially responsivepeople with schizophrenia treated with clozapine.  Neuropsychopharmacology 35(11):2274-2283, 2010.  PMCID:PMC2939921

Weiner E.  Lessons from Jimmy.  American Journal of Psychiatry 168(3):243-244, 2011.

Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL.  Varenicline for smoking cessation in people with schizophrenia: A double blind randomized pilot study.  Schizophrenia Research 129(1):94-95, 2011.

 Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon R, Buchanan RW.  Bupropion sustained release added to group support for smoking cessation in schizophrenia: new randomized trial data and a meta-analysis.  Journal of Clinical Psychiatry 73(1):95-102, 201

Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA. Rasagline in the treatment of the persistent negative symptoms of schizophrenia.  Schizophrenia Bulletin 41(4):900-908, 2015.  PMID:25368372; PMCID: PMC4466175; DOI:10.1093/schbul/sbu151.

Wehring HJ, Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H, Weiner E, Kelly DL. Antipsychotic treatment and tobacco craving in people with schizophrenia.  Journal of Dual Diagnosis 13(1):36042, 2017.  PMID:28166471; PMCID: PMC5379991; DOI: 10.1080/15504263.2017.1288946.

Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT. A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia.  Journal of Clinical Psychopharmacology 37(4):394-400, 2017.  PMID:28590362; PMCID: PMC5484721; DOI: 10.1097/JCP.0000000000000720.

Buchanan RW, Weiner E, Kelly DL, Gold JM, Chen S, Zaranski J, Blatt F, Wehring H, Carpenter WT. Anti-inflammatory combination therapy for the treatment of schizophrenia.  Journal of Clinical Psychopharmacology 40(5):444-450, 2020.  PMID: 32796391; DOI:  1097/JCP.0000000000001253.

Buchanan RW, Kelly DL, Strauss GP, Gold JM, Weiner E, Zaranski J, Shuo C, Blatt F, Holden J, Granholm E. Combined oxytocin and CBSST for social function in people with schizophrenia.  The Journal of Clinical Psychopharmacology, 41(3):236-243, 2021. PMID: 33783399; DOI: 1097/JCP.0000000000001397



Clinical Specialty Details

Schizophrenia; Treatment of Schizophrenia with group therapy and medication management, and the use of Cognitive Behavioral Therapy and Acceptance Commitment Therapy to target residual positive and negative symptoms.